Key Insights

Highlights

Success Rate

85% trial completion

Published Results

100 trials with published results (14%)

Research Maturity

343 completed trials (48% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

8.5%

60 terminated out of 709 trials

Success Rate

85.1%

-1.5% vs benchmark

Late-Stage Pipeline

6%

43 trials in Phase 3/4

Results Transparency

29%

100 of 343 completed with results

Key Signals

100 with results85% success60 terminated

Data Visualizations

Phase Distribution

498Total
Not Applicable (155)
Early P 1 (12)
P 1 (132)
P 2 (156)
P 3 (38)
P 4 (5)

Trial Status

Completed343
Recruiting106
Unknown99
Terminated60
Active Not Recruiting36
Withdrawn28

Trial Success Rate

85.1%

Benchmark: 86.6%

Based on 343 completed trials

Clinical Trials (709)

Showing 20 of 20 trials
NCT06726577Phase 1RecruitingPrimary

TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis

NCT07855211Phase 1Not Yet RecruitingPrimary

A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS)

NCT07204977Phase 1RecruitingPrimary

Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)

NCT05039099Phase 2CompletedPrimary

A Study to Evaluate, Safety, Tolerability, and PK of AP-101 in Participants With ALS

NCT04220190Phase 2RecruitingPrimary

RAPA-501 Therapy for ALS

NCT05163886Phase 2CompletedPrimary

Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis

NCT04721717Completed

AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis

NCT05407324Phase 2Active Not RecruitingPrimary

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

NCT07290062Phase 1RecruitingPrimary

A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT07834450Phase 2Not Yet RecruitingPrimary

Efficacy and Safety of Cyclophosphamide in Amyotrophic Lateral Sclerosis

NCT07571174Phase 1RecruitingPrimary

A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

NCT07571200Phase 1RecruitingPrimary

A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT07322003Phase 3RecruitingPrimary

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

NCT01925196CompletedPrimary

Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation

NCT05744310Not ApplicableRecruitingPrimary

Effects of Long Term Ventilation Support on the Quality of Life of ALS Patients and Their Families

NCT06881979Not ApplicableRecruitingPrimary

High-Tech Rehabilitation Pathway for Chronic Adult Neuromuscular Diseases - Fit4MedRob-Chronic MND Project

NCT05095571Not ApplicableActive Not RecruitingPrimary

A Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Extension Study

NCT04031469Suspended

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT03225144Recruiting

Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

NCT05297487Not ApplicableWithdrawnPrimary

Evaluation of the Early Use of the Pressure Relaxer in the Respiratory Impairment of Patients With Amyotrophic Lateral Sclerosis: Multicenter Randomized Controlled Study.

Scroll to load more

Research Network

Activity Timeline